Cozad Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Cozad Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,405	Closed	-$699K	–	249
2019 Q2	$699K	Sell	6,405 -120	-2%	-$12.8K	0.2%	121
2019 Q1	$729K	Sell	6,525 -715	-10%	-$78.4K	0.22%	118
2018 Q4	$698K	Hold	7,240	–	–	0.24%	115
2018 Q3	$883K	Hold	7,240	–	–	0.26%	106
2018 Q2	$795K	Buy	+7,240	New	+$774K	0.25%	106

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Cozad Asset Management's IBB Position: Q3 2019 in Review

Cozad Asset Management sold out of iShares Biotechnology ETF (IBB) in Q3 2019, closing a stake of 6,405 shares — an estimated $699K sold.

Cozad Asset Management first reported a position in IBB in Q2 2018 and held it in 5 quarters. The position peaked at $883K in Q3 2018. 597 funds tracked by Wall St. Rank hold IBB as of Q3 2019.

Cozad Asset Management reported no remaining iShares Biotechnology ETF position as of Q3 2019 after selling out during the quarter.
Cozad Asset Management sold 6,405 iShares Biotechnology ETF shares in Q3 2019, an estimated $699K.
Cozad Asset Management first reported a position in iShares Biotechnology ETF in Q2 2018 and held it in 5 quarters.
Cozad Asset Management's iShares Biotechnology ETF position peaked at $883K in Q3 2018.
597 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2019.

Based on Cozad Asset Management's 13F filing for Q3 2019, filed 31 Oct 2019.